Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Gynecologic 1 Gastrointestinal 1

Conditions

Ovarian Neoplasms 4 Fallopian Tube Neoplasms 2 Uterine Cervical Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 19 Paclitaxel 17 Cisplatin 9 Cyclophosphamide 8 Gemcitabine 7 Bevacizumab 6 Topotecan 5 pembrolizumab 4 olaparib 4 liposomal doxorubicin 4 durvalumab 4 Letrozole 4 Interleukin-2 4 Drug Therapy 4 Doxorubicin 4 Albumin-Bound Paclitaxel 4 rucaparib 3 fludarabine 3 chiauranib 3 cemiplimab 3 camrelizumab 3 Therapeutics 3 Itraconazole 3 Injections 3 Hyperthermic Intraperitoneal Chemotherapy 3 Everolimus 3 pazopanib 2 iniparib 2 eprenetapopt 2 avelumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Panitumumab × Gynecologic × Clear all

NCT01388621 2013-08-20

PROVE

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Unknown

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡